Latest news with #WRN
Yahoo
4 days ago
- Business
- Yahoo
Bayer subsidiary Vividion secures rights to Werner helicase inhibitor
Bayer subsidiary Vividion Therapeutics has secured exclusive worldwide rights to develop and commercialise VVD-214, the Werner helicase (WRN) covalent inhibitor, enhancing its oncology pipeline. Roche and Vividion discovered and developed VVD-214 through a global partnership and licence agreement. In 2020, the companies agreed to discover and develop small molecules for a range of therapeutic targets. The acquisition of VVD-214 rights by Vividion complements its portfolio of investigational therapeutics aimed at treating cancers and immune disorders. Preliminary data from a Phase I trial indicated that the therapy is well-tolerated and exhibits signs of activity. The trial is assessing VVD-214 as a single agent and in conjunction with pembrolizumab for those with various solid tumours showing microsatellite instability (MSI), such as endometrial, colorectal, gastric and ovarian cancers. WRN is a deoxyribonucleic acid (DNA) repair enzyme and a synthetic lethal target for cancers with MSI. VVD-214's mechanism aims to induce lethal DNA damage in these cancers while sparing healthy cells. This approach could offer a new treatment avenue for patients with limited options, particularly those who relapse or become refractory to immune checkpoint inhibitors. Vividion Therapeutics CEO Aleksandra Rizo stated: 'Bringing VVD-214, the only clinical-stage covalent inhibitor of WRN in development worldwide, into our portfolio marks an incredibly exciting moment for Vividion. 'We are eager to progress development of this compound, building on the encouraging clinical data we've seen to date, as part of our mission to transform treatment for patients with cancer and other serious diseases.' Vividion has Phase I trials for other potential oral cancer therapies, including a Kelch-like ECH-associated protein 1 (KEAP1) activator, a RAS-phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor and a signal transducer and activator of transcription 3 (STAT3) inhibitor. The company is progressing the discovery of several drug programmes towards the clinic and has a pipeline of early discovery opportunities in immunology and oncology, utilising its chemoproteomics platform. "Bayer subsidiary Vividion secures rights to Werner helicase inhibitor" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Bayer subsidiary Vividion secures rights to Werner helicase inhibitor
Bayer subsidiary Vividion Therapeutics has secured exclusive worldwide rights to develop and commercialise VVD-214, the Werner helicase (WRN) covalent inhibitor, enhancing its oncology pipeline. Roche and Vividion discovered and developed VVD-214 through a global partnership and licence agreement. In 2020, the companies agreed to discover and develop small molecules for a range of therapeutic targets. The acquisition of VVD-214 rights by Vividion complements its portfolio of investigational therapeutics aimed at treating cancers and immune disorders. Preliminary data from a Phase I trial indicated that the therapy is well-tolerated and exhibits signs of activity. The trial is assessing VVD-214 as a single agent and in conjunction with pembrolizumab for those with various solid tumours showing microsatellite instability (MSI), such as endometrial, colorectal, gastric and ovarian cancers. WRN is a deoxyribonucleic acid (DNA) repair enzyme and a synthetic lethal target for cancers with MSI. VVD-214's mechanism aims to induce lethal DNA damage in these cancers while sparing healthy cells. This approach could offer a new treatment avenue for patients with limited options, particularly those who relapse or become refractory to immune checkpoint inhibitors. Vividion Therapeutics CEO Aleksandra Rizo stated: 'Bringing VVD-214, the only clinical-stage covalent inhibitor of WRN in development worldwide, into our portfolio marks an incredibly exciting moment for Vividion. 'We are eager to progress development of this compound, building on the encouraging clinical data we've seen to date, as part of our mission to transform treatment for patients with cancer and other serious diseases.' Vividion has Phase I trials for other potential oral cancer therapies, including a Kelch-like ECH-associated protein 1 (KEAP1) activator, a RAS-phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor and a signal transducer and activator of transcription 3 (STAT3) inhibitor. The company is progressing the discovery of several drug programmes towards the clinic and has a pipeline of early discovery opportunities in immunology and oncology, utilising its chemoproteomics platform. "Bayer subsidiary Vividion secures rights to Werner helicase inhibitor" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business Wire
5 days ago
- Business
- Business Wire
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor
SAN DIEGO & BERLIN, Germany--(BUSINESS WIRE)-- Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced it has secured exclusive worldwide rights to develop and commercialize the clinical-stage Werner helicase (WRN) covalent inhibitor VVD-214 (RO7589831), strengthening and complementing its innovative oncology development pipeline. VVD-214 was discovered and developed under an exclusive worldwide collaboration and license agreement initiated between Vividion and Roche in 2020. Vividon utilizes innovative discovery technologies to unlock difficult-to-drug targets with strong disease-links, and to develop small molecule precision therapeutics for devastating cancers and immune disorders. Preliminary data from a first-in-human study presented at the recent American Association for Cancer Research (AACR) Annual Meeting showed that VVD-214 is well tolerated and has promising signs of activity. Vividion will continue the clinical development of VVD-214 within the company's pipeline of innovative investigational therapeutics for cancers and immune disorders. WRN is a DNA repair enzyme and a highly sought-after synthetic lethal target for treatment of cancers with microsatellite instability (MSI). By inhibiting WRN, VVD-214 aims to cause lethal DNA damage in cancers with high microsatellite instability while minimizing harm to healthy cells. 'Bringing VVD-214, the only clinical-stage covalent inhibitor of WRN in development worldwide, into our portfolio marks an incredibly exciting moment for Vividion,' said Aleksandra Rizo, M.D., Ph.D., Chief Executive Officer of Vividion. 'We are eager to progress development of this compound, building on the encouraging clinical data we've seen to date, as part of our mission to transform treatment for patients with cancer and other serious diseases.' The Phase I clinical trial (NCT06004245) is evaluating VVD-214 as a monotherapy and in combination with pembrolizumab as a treatment option for patients with solid tumors that display high MSI or deficient mismatch repair (dMMR) including but not limited to colorectal, endometrial, ovarian and gastric cancers. Treatment options for these patients today are limited, and a majority will relapse or become refractory to immune checkpoint inhibitors. The initial data, recently presented at AACR by Timothy Yap, M.B.B.S., Ph.D., clinical investigator and professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, showed early signals of efficacy for VVD-214 in a range of solid tumor types with high MSI. 1 'VVD-214 is showing promising potential to improve treatment options for patients suffering from MSI-high cancers, a population with high unmet medical need,' said Christian Rommel, Ph.D., Global Head of Research and Development at Bayer's Pharmaceuticals Division. 'It underscores the ability of Vividion's chemoproteomics technology to identify and advance new treatment opportunities for challenging and intractable diseases, and will be a valuable addition to the company's portfolio.' Vividion also has ongoing Phase I trials evaluating an oral KEAP1 activator in solid tumors, an oral STAT3 inhibitor in solid and hematologic malignancies, and an oral RAS-PI3Kα inhibitor in advanced solid tumors. The company is advancing multiple innovative drug discovery programs toward the clinic and has a growing pipeline of opportunities emerging in early discovery in the fields of oncology and immunology leveraging its chemoproteomics platform. About Vividion Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock difficult-to-drug targets with strong disease-links, and to develop small molecule precision therapeutics for devastating cancers and immune disorders. The company's platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets. The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high-value, traditionally undruggable targets in oncology and immunology. For more information, please visit About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to aka (2025-0105) Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Washington Post
08-05-2025
- Business
- Washington Post
Western Copper: Q1 Earnings Snapshot
VANCOUVER, British Columbia — VANCOUVER, British Columbia — Western Copper and Gold Corp. (WRN) on Thursday reported a loss of $444,000 in its first quarter. The Vancouver, British Columbia-based company said it had a loss of less than 1 cent on a per-share basis. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on WRN at
Business Wire
25-04-2025
- Business
- Business Wire
Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced that its Phase 1/2 clinical trial of NDI-219216, the company's investigational non-covalent Werner syndrome helicase (WRN) inhibitor, is actively enrolling and dosing patients with advanced solid tumors. "The initiation of this clinical trial marks an important milestone in advancing our novel WRN inhibitor program," said Anita Scheuber, M.D., Ph.D., Senior Vice President, Therapeutic Head, Oncology at Nimbus. "We are excited to be evaluating NDI-219216 in patients with advanced disease, who currently have limited treatment options when they experience disease progression on standard of care therapies. The trial is actively enrolling across multiple clinical sites, and we look forward to generating important additional safety and efficacy data as we advance this promising candidate through clinical development." The Phase 1/2 clinical trial (NCT06898450) is an open-label, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of NDI-219216 in patients with advanced cancer. The study will be conducted in three parts: Part A (dose escalation), Part B (dose optimization), and Part C (dose expansion). Nimbus presented promising preclinical data on NDI-219216 (previously NTX-452) at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in October 2024. The data demonstrate that NDI-219216 is a potent and selective WRN inhibitor with significant tumor regression and sustained complete responses observed at low doses in MSI-H tumor models refractory to immunotherapy and chemotherapy. The company will present new findings comparing covalent versus non-covalent WRN inhibition mechanisms and demonstrating NDI-219216's superior efficacy across multiple preclinical MSI-H tumor models compared with other clinical-stage WRN inhibitors in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025 in Chicago. The poster entitled "NDI-219216: a non-covalent, potent, selective and highly efficacious WRN inhibitor with best-in-class potential for the treatment of MSI-H tumors" highlights key preclinical findings related to NDI-219216, including: Demonstration of activity against a potential resistance mutation at Cysteine 727 that could significantly reduce the efficacy of covalent WRN inhibitors Robust tumor regression across multiple MSI-H tumor models, including those that are refractory to existing standard of care agents Superior efficacy at lower doses and in less responsive MSI-H tumor models compared to other clinical-stage WRN inhibitors "The data we are presenting at AACR 2025 highlight several important features of our non-covalent WRN inhibitor," said Peter J. Tummino, Ph.D., President of Research and Development at Nimbus. "NDI-219216 has the potential for more durable target engagement than covalent inhibitors and maintains potency against potential resistance mutations. Its superior efficacy across multiple MSI-H tumor models, including those less sensitive to other WRN inhibitors and those refractory to current therapies, reinforces our belief that NDI-219216 represents a best-in-class opportunity with broad potential across multiple MSI-H tumor types with significant unmet need." About NDI-219216 NDI-219216 is a highly potent and selective non-covalent investigational inhibitor of Werner syndrome helicase (WRN) activity being developed for the treatment of MSI-H tumors. WRN is a DNA helicase required for DNA replication and DNA repair and is a validated synthetic lethal target for tumors with microsatellite instability (MSI). MSI is a phenotypic consequence of deficient mismatch repair (dMMR) and occurs in various tumor types, including colorectal, gastric, and endometrial cancers. In preclinical studies, treatment with NDI-219216 exhibited robust antitumor activity across multiple cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) MSI-H tumor models, including models for colorectal, gastric, and endometrial cancers. About Nimbus Therapeutics Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus' pipeline includes a WRN inhibitor in Phase 1/2 clinical development (NCT06898450) and a diverse portfolio of preclinical programs across oncology, immunology, and metabolism, including a SIK inhibitor program and other undisclosed metabolic targets. The company is headquartered in Boston, Mass. To learn more about Nimbus, please visit
